|
Lung Cancer Awareness Month
November marks Lung Cancer Awareness Month to raise awareness about lung cancer, its risk factors, prevention strategies, the importance of early detection through screenings, and to defeat the stigma associated with the disease. According to the American Cancer Society, lung cancer is one of the most prevalent and deadly types of cancer. Still, timely interventions and lifestyle changes significantly reduce the risk of lung cancer. Highlighting the impact of lung cancer urges organizations, medical professionals, and communities to promote awareness, education, and advocacy efforts in the fight against lung cancer, helping reduce the burden of this devastating disease and providing treatment and support for patients and families.
There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With 80-85% of lung cancers being NSCLC, immunotherapy is a widely established standard of care treatment modality for patients with advanced-stage NSCLC. Unfortunately, research indicates that lower socioeconomic status exists in access to care among NSCLC patients, therefore limiting patients’ ability to participate in clinical trials that are evaluating new approaches to treatment and prevention methods for lung cancer. Dismantling social determinants of health barriers is essential to reduce the percentage of patients who do not receive any treatment and ensures that those at high risk for lung cancer have access to community oncology centers and clinical trials.
Upstate Carolina NCORP would like to highlight three clinical trials that we participate in that focus on Non-Small Cell Lung Cancer (NSCLC):
S2302: PRAGMATICA – LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy For Stage IV or Recurrent Non-Small Cell Lung Cancer
-
Primary Objective: To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and immunotherapy for Stage IV or recurrent non-small cell lung cancer (NSCLC) randomized to pembrolizumab and ramucirumab versus stand or care.
S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early-Stage NSCLC
-
Primary Objective: To compare overall survival (OS) in patients with inoperable, early-stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
NCI 10323: Cancer Moonshot Biobank Research Protocol
- Primary Objective: To support current and future investigations into drug resistance and sensitivity and other NCI-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCORP sites.
For more information about these trials and others, follow the link to our website.
| 
